argenx SE
Argenx SE is a global immunology company developing antibody-based therapies, with its sole political signal being a $1,001-$15,000 sale of its ADRs by a Trump-era executive branch official.
BusinessWhat ARGX does
Argenx SE is a biotechnology company focused on creating antibody-based therapeutics for severe autoimmune diseases and cancer. Its commercial product is Vyvgart (efgartigimod), a neonatal Fc receptor blocker for generalized myasthenia gravis. Revenue is generated from product sales and collaboration agreements.
12 months past · 3 months futureARGX activity timeline
Executive Branch ConflictsARGX held by Trump-administration officials
Lifetime Government AwardsARGX federal contracts
ARGX doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding ARGX
Congressional TradesWho in Congress is trading ARGX
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting ARGXLive legislation impacting this stock
Political ProfileWhere ARGX sits in Washington
[object Object]
STRUCTURAL: No lobbying spend (`get_political_influence.lobbying.total_income`: $0), no donations, no federal contracts (`get_government_precedent.federal_contracts_summary`: null). EVIDENTIARY: Single executive branch filer (Sean Duffy) held and sold ADRs (`get_executive_branch_exposure.by_ticker[0].holdings`), but transaction value is low ($1,001-$15,000 bucket). No congressional trades or corporate insider buys in 180 days (`get_corporate_insider_signal.total_buys`: 0). Net: Minimal direct political engagement or activity.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
High exposure to general healthcare pricing and reimbursement legislationCongress, HHS/CMS"`bill_impacts` lists 8 healthcare bills with uniform 0.0001 impact_ratio, indicating broad sector sensitivity."
Regulatory opportunities
-
None identified from structured data.N/A"`get_political_influence.lobbying` shows $0 spend and 0 filings; `bill_carveouts` is empty."
Live signals + predictions for ARGX — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades ARGX
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord